Cefepime-Enmetazobactam (formerly AAI101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design

Michael D. Huband¹, Kelley A. Fedler¹, Amy A. Watters¹, A Belley², Philipp Knechtle², Robert K. Flamm¹ ¹ JMI Laboratories, North Liberty, Iowa, USA; ² Allecra Therapeutics SAS, Saint-Louis, France

Introduction

- Standard therapies for the treatment of serious Gram-negative infections by thirdgeneration cephalosporin (3GC)-resistant Enterobacteriaceae are losing efficacy. As a result, carbapenems are used more frequently in settings with a high prevalence of **3GC-resistance**
- Carbapenem-resistant and 3GC-resistant Enterobacteriaceae have been categorized as "critical priority" pathogens by the World Health Organization
- Enmetazobactam (formerly AAI101) is a novel extended-spectrum β -lactamase inhibitor that targets 3GC-resistant Enterobacteriaceae
- Cefepime-enmetazobactam is intended for the empiric treatment of serious gramnegative infections in settings with an elevated prevalence of ESBL-producing Enterobacteriaceae
- Cefepime-enmetazobactam (2g/0.5g) administered q8h has recently entered phase 3 clinical trials in patients with complicated urinary tract infections and pyelonephritis (NTC03687255)
- In this study, Clinical and Laboratory Standards Institute (CLSI) M23 (2018) Tier-2 Quality Control (QC) studies were conducted to establish disk diffusion QC ranges for cefepime-enmetazobactam ($30/20 \mu g$) and cefepime ($30 \mu g$) disks against CLSI reference strains

Materials and Methods

- The bacterial OC reference strains tested were *Escherichia coli* ATCC 25922 (β-lactamase-negative), *E. coli* ATCC 35218 (non-ESBL, TEM-1 β-lactamase producing), E. coli NCTC 13353 (CTM-15, ESBL-producing), Klebsiella pneumoniae ATCC 700603 (SHV-18, ESBL-producing), and Pseudomonas aeruginosa ATCC 27853
- CLSI M23 Tier-2 disk diffusion QC testing utilized at least 8 participating laboratories (Table 1), 3 lots of Mueller-Hinton agar medium obtained from 3 manufacturers, and \geq 10 replicate tests per QC strain
- Testing was performed over a minimum of 3 days with no more than 4 replicates tested per day
- Mueller-Hinton agar for disk diffusion susceptibility testing was obtained from Remel (Thermo Fisher Scientific: Waltham, Massachusetts, medium lot A), Becton Dickinson (BBL; Franklin Lakes, NJ, medium lot B), and Hardy Diagnostics (Santa Maria, California, medium lot C)
- Disk diffusion testing employed 2 lots of cefepime-enmetazobactam $(30/20 \mu g)$ disks obtained from Oxoid (Thermo Fisher Scientific) and 2 lots of cefepime (30 µg) disks obtained from Becton Dickinson (BBL) and Oxoid (Thermo Fisher Scientific)
- Inoculum densities were monitored by bacterial colony counts
- 2 cefepime-enmetazobactam (30/20 µg) inhibition zone diameter values were generated for 3 media lots at 8 independent laboratories over 10 replicates totaling 480 zone diameter values; a minimum of 420 inhibition zone diameter values are required to fulfil CLSI M23 criteria
- Inhibition zone diameter ranges for each QC reference strain were calculated using the Gavan statistic and RangeFinder statistical program

Results

- 7 mm QC ranges containing 97.1%-100.0% of all cefepime-enmetazobactam $(30/20 \ \mu g)$ disk diffusion zone diameter values were approved at the January 2019 CLSI meeting for *E. coli* ATCC 25922 (32-38 mm), *E. coli* ATCC 35218 (32-38 mm), E. coli NCTC 13353 (27-33 mm), K. pneumoniae ATCC 700603 (26-32 mm), and P. aeruginosa ATCC 27853 (26-32 mm) (Table 2 and Figures 1-5)
- A 7 mm QC range (31-37 mm) containing 100.0% of cefepime (30 µg) zone diameter values was approved at the January 2019 CLSI meeting for E. coli ATCC 35218 (Table 2 and Figure 6)

Table 1 Investigators and laboratories participating in the CLSI M23 disk diffusion quality control study

estigator Flamm, PhD . Knapp, MS D. Dressel, MS

D. Snydman, M . Bobenchik, D. Hardy, PhD C. Pillar, PhD

. Denys, PhD

Table 2 CLSI approved disk diffusion QC ranges for cefepimeenmetazobactam $(30/20 \mu g)$ and cefepime $(30 \mu g)$ against reference strains

ference stra

scherichia col

Scherichia co

scherichia col

lebsiella pneu

Pseudomonas 27853

PE, cefepime-enmetazobactam (30/20 µg). Current CLSI OC range.

Figure 1 Cefepime-enmetazobactam (30/20 µg) disk distributions by medium lot for *E. coli* ATCC 25922



Colony counts were performed on each of the QC reference strains and results were within acceptable inoculum targets of 1-2 x 10⁸ CFU/mL for a 0.5 McFarland standard Against cefepime (30 µg) tested alone, 97.1% (466/480), 99.5% (418/420), 99.8% (479/480), and 99.2% (476/480) of the inhibition zone diameter values against E. coli ATCC 25922, E. coli NCTC 13353, K. pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853, respectively, were within current CLSI-approved QC ranges, providing validated internal controls on each day of susceptibility testing

	Participating Laboratory and Location		
	JMI Laboratories, North Liberty, Iowa, USA		
	Thermo Fisher Scientific, Oakwood Village, Ohio, USA		
	International Health Management Associates, Schaumberg, Illinois, USA		
)	Tufts University Medical Center, Boston, Massachusetts, USA		
nD	Rhode Island Miriam Hospital, Providence, Rhode Island, USA		
	University of Rochester Medical Center, Rochester, New York, USA		
	Micromyx Inc., Kalamazoo, Michigan, USA		
	Indiana University Health, Methodist Hospital, Indianapolis, Indiana,		

	Approved CLSI disk diffusion QC ranges (mm)	
	FPE ^a (30/20 μg)	Cefepime (30 µg)
TCC 25922	32 – 38 (7 mm)	31 – 37 ^b (7 mm)
TCC 35218	32 – 38 (7 mm)	31 – 37 (7 mm)
ICTC 13353	27 – 33 (7 mm)	6 – 15 ^b (10 mm)
oniae ATCC 700603	26 – 32 (7 mm)	23 – 29 ^b (7 mm)
ruginosa ATCC	26 – 32 (7 mm)	25 – 31 ^b (7 mm)







Figure 2 Cefepimeenmetazobactam $(30/20 \mu g)$ disk distributions by medium lot for E. coli ATCC 35218

Figure 3 Cefepimeenmetazobactam $(30/20 \ \mu g) \ disk$ distributions by medium lot for *E. coli* NCTC 13353



Figure 4 Cefepimeenmetazobactam $(30/20 \mu g)$ disk distributions by medium lot for K. pneumoniae ATCC 700603

Figure 5 Cefepimeenmetazobactam $(30/20 \ \mu g) \ disk$ distributions by medium lot for P. aeruginosa ATCC 27853



Figure 6 Cefepime (30 µg) disk distributions by medium lot for *E. coli* ATCC 35218

Conclusions

- 7 mm QC ranges containing 97.1-100.0% of all cefepime-enmetazobactam (30/20 µg) disk diffusion zone diameter values were approved for *E. coli* ATCC 25922, E. coli ATCC 35218, E. coli NCTC 13353, K. pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853 at the January 2019 CLSI meeting
- A 7 mm QC range containing 100.0% of cefepime (30 μg) zone diameter values was approved for E. coli ATCC 35218 at the January 2019 CLSI meeting
- E. coli NCTC 13353 is recommended for routine QC testing of cefepimeenmetazobactam (30/20 μ g) disks as it can effectively control for both β -lactamase activity (hydrolysis of cefepime by CTX-M-15) and inhibition (by enmetazobactam)
- Established disk diffusion QC ranges for cefepime-enmetazobactam (30/20 µg) disks will ensure that appropriate disk diffusion QC standards are implemented by reference and clinical laboratories

Acknowledgements

This study and poster presentation were funded by a grant from Allecra Therapeutics SAS (Saint-Louis, France).

References

Clinical and Laboratory Standards Institute (2019). M100Ed29E. Performance standards for antimicrobial susceptibility testing: 29th informational supplement. Wayne, PA: CLSI. Clinical and Laboratory Standards Institute. (2018) M23Ed5E. Development of in vitro susceptibility testing criteria and quality control parameters, 5th edition. Wayne, PA: CLS

Clinical and Laboratory Standards Institute. (2018) M02Ed13E. Performance standards for antimicrobal disk susceptibility tests; Thirteenth Edition. Wayne, PA: CLSI. Gavan TL, Jones RN, Barry AL, Fuchs PC, Gerlach EH, Matsen JM, Reller LB, Thornsberry C and Thrupp LD. Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study. J. Clin. Microbiol. 14: 67-72: 1981.

Turnidge J and Bordash G. Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing. Antimicrob. Agents Chemother. 51: 2483-2488: 2007.

Contact

Michael D. Huband JMI Laboratories 345 Beaver Kreek Centre, Suite A North Liberty, IA 52317 Phone: (319) 665-3370 Fax: (319) 665-3371 Email: michael-huband@jmilabs.com



To obtain a PDF of this poster: Scan the QR code or visit https://www .jmilabs.com/data/posters/ECCMID19 -cefepime-enmetazobactam-disk.pdf

Charges may apply. No personal information is stored.